$4.70
-0.42%Kalaris Therapeutics Inc operates as a pharmaceutical company. The Company specializes in the development of novel cell therapies with a focus on restoring natural immunity against life-threatening virus-associated diseases in patients with severely weakened immune systems.
Excellent liquidity position. The company can easily cover its short-term obligations with substantial cushion.
Balanced capital structure with moderate leverage. Equity exceeds debt, suggesting healthy financial stability.
Strong working capital position provides significant operational flexibility and financial cushion.
Asset-light business model with high liquidity. Majority of assets are easily convertible to cash.
Strong financial foundation: Excellent liquidity combined with conservative leverage suggests the company is well-positioned to weather economic uncertainties and fund growth opportunities.
KLRS • NASDAQ
| Kalaris Therapeutics Inc Balance Sheet | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
ASSETS | ||||||
CURRENT ASSETS | ||||||
98.1M | 118.3M | 3.2M | 3.1M | 201.7M | 122.7M | |
19.9M | 0.0 | 0.0 | 0.0 | 46.5M | 233.7M | |
118M | 118.3M | 3.2M | 3.1M | 248.1M | 356.3M | |
0.0 | 0.0 | 0.0 | 0.0 | 50K | 450K | |
0.0 | 0.0 | 0.0 | 0.0 | 50K | 450K | |
749K | 0.0 | 164K | 840K | 0.0 | 0.0 | |
78K | 257K | 0.0 | 0.0 | 5.2M | 4.5M | |
118.8M | 118.5M | 3.3M | 3.9M | 253.3M | 361.3M | |
NON-CURRENT ASSETS | ||||||
1.5M | 0.0 | 0.0 | 0.0 | 31.3M | 9.5M | |
499K | 0.0 | 0.0 | 0.0 | 852K | 0.0 | |
953K | 0.0 | 0.0 | 0.0 | 1.1M | 0.0 | |
2.9M | 0.0 | 0.0 | 0.0 | 33.2M | 9.5M | |
121.7M | 118.5M | 3.3M | 3.9M | 286.6M | 370.8M | |
LIABILITIES | ||||||
CURRENT LIABILITIES | ||||||
1.3M | 247K | 2.4M | 2.8M | 9.4M | 963K | |
1.3M | 247K | 2.4M | 2.8M | 8.4M | 963K | |
0.0 | 0.0 | 13K | 21K | 1M | 0.0 | |
1.6M | 3M | 1M | 2.6M | 6.9M | 3.3M | |
316K | 0.0 | 0.0 | 0.0 | 6.6M | 3.2M | |
6.5M | 2M | 540K | 296K | 15M | 4.8M | |
9.7M | 5.2M | 3.9M | 5.7M | 37.9M | 12.3M | |
NON-CURRENT LIABILITIES | ||||||
0.0 | 0.0 | 0.0 | 3.3M | 0.0 | 0.0 | |
32.1M | 0.0 | 44.4M | 25.2M | 0.0 | 0.0 | |
33.2M | 0.0 | 44.4M | 28.5M | 23.5M | 5.5M | |
1.1M | 0.0 | 0.0 | 0.0 | 23.5M | 5.5M | |
42.9M | 5.2M | 48.4M | 34.2M | 61.3M | 17.8M | |
SHAREHOLDERS' EQUITY | ||||||
2K | 0.0 | 0.0 | 0.0 | 7K | 7K | |
238.8M | 828.4M | 2.4M | 2.4M | 522.5M | 478.3M | |
-160M | -715M | -47.4M | -32.7M | -297.1M | -125.1M | |
6K | -135K | 0.0 | 0.0 | -155K | -112K | |
78.8M | 113.3M | -45M | -30.3M | 225.3M | 353.1M | |
78.8M | 113.3M | -45M | -30.3M | 225.3M | 353.1M | |
SUMMARY | ||||||
121.7M | 118.5M | 3.3M | 3.9M | 286.6M | 370.8M | |
20.4M | 0.0 | 0.0 | 0.0 | 47.3M | 233.7M | |
1.4M | 0.0 | 0.0 | 3.3M | 30.1M | 8.7M | |
-96.6M | -118.3M | -3.2M | 194K | -171.6M | -114M | |
18,702,418 | 18,702,418 | 18,702,418 | 18,702,418 | 18,702,418 | 18,702,418 |
KLRS - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
10-Q 10-Q 2026 Q1 Q1 | May 12, 2026 | March 31, 2026 | 2026 | |
8-K 8-K 2026 N/A | May 12, 2026 | May 12, 2026 | 2026 | |
DEF 14A DEF 14A 2026 N/A | April 24, 2026 | June 03, 2026 | 2026 | |
8-K 8-K 2026 N/A | April 10, 2026 | April 08, 2026 | 2026 | |
S-3 S-3 N/A | April 03, 2026 | April 03, 2026 | ||
S-3 S-3 N/A | April 03, 2026 | April 03, 2026 | ||
10-K 10-K 2025 FY FY | March 17, 2026 | December 31, 2025 | 2025 | |
8-K 8-K 2026 N/A | March 17, 2026 | March 17, 2026 | 2026 | |
8-K 8-K 2026 N/A | March 09, 2026 | March 09, 2026 | 2026 | |
8-K 8-K 2025 N/A | December 18, 2025 | December 17, 2025 | 2025 |
Continue your KLRS research with focused valuation guides.
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.